Please use this identifier to cite or link to this item:
Title: Comparative study of centrally acting muscle relaxants in spasticity associated with post stroke celebral palsy and spinal cord injury
Researcher: Agarwal Saurabh
Guide(s): Patel Bhoomika M
Keywords: cerebral palsy
University: Nirma University
Completed Date: 28/08/2017
Abstract: Spasticity is a clinical sign of upper motor neuron dysfunction. It occurs due to defects in inhibitory descending spinal motor pathways. The aim of the treatment of spasticity is to facilitate rehabilitation, increase daily activities, prevent contractures and relieve pain. Nowadays, physiotherapy is becoming a very common practice in the rehabilitative management of spasticity. Stretching can increase the extensibility of soft tissues by a mechanism that involves viscous deformation and structural adaptations of muscle and other soft tissues. Oral baclofen is one of the most common drug used for the treatment of spasticity on a long term basis. It has been reported that baclofen causes reduction in hyperreflexia, muscle tone and contractions of paraylzed muscles. The muscle activity reductions though suggest induction of long-term disuse effects in muscle by baclofen. Infact, it has been reported that patients with SCI or multiple sclerosis have complaints of muscle weakness and reduced voluntary functions after few weeks. In the past two decades, BTX-A has been introduced with an aim to reduce spasticity in children with CP. The benefits of BTX-A treatment include a reduction in muscle tone, increased joint ROM, improved gait patterns, and functional improvements. There is a known association between the use of BTX-A and muscle weakness, with reports of generalised muscle weakness and weakness in neighbouring non-targeted muscles. From last few years, tolperisone has presented itself as a very effective and safe muscle relaxant in all types of spasticities. Tolperisone has different pharmacological properties than other myotonolytic agents viz. absence of sedation or withdrawal phenomenon. Only few studies are available evaluating the safety and efficacy profile of tolperisone in post-stroke spasticity and no reports are available for SCI and CP related spasticity. newline
Appears in Departments:Institute of Pharmacy

Files in This Item:
File Description SizeFormat 
10_chapter2.pdfAttached File1.17 MBAdobe PDFView/Open
11_chapter3.pdf401.26 kBAdobe PDFView/Open
12_chapter4.pdf944.01 kBAdobe PDFView/Open
13_chapter5.pdf320.44 kBAdobe PDFView/Open
14_summary&conclusion.pdf156.16 kBAdobe PDFView/Open
15_bibliography.pdf586.62 kBAdobe PDFView/Open
1_title.pdf489.47 kBAdobe PDFView/Open
2_certificate final.pdf347.56 kBAdobe PDFView/Open
5_acknowladgement.pdf113.09 kBAdobe PDFView/Open
6_contents.pdf40.86 kBAdobe PDFView/Open
7_list_of_tables.pdf7.86 kBAdobe PDFView/Open
8_list_of_figures.pdf149.55 kBAdobe PDFView/Open
9_chapter1.pdf297.56 kBAdobe PDFView/Open

Items in Shodhganga are protected by copyright, with all rights reserved, unless otherwise indicated.